1. <th id="ya0vw"><sup id="ya0vw"></sup></th>
      <pre id="ya0vw"><small id="ya0vw"><input id="ya0vw"></input></small></pre>
    2. <pre id="ya0vw"><small id="ya0vw"><p id="ya0vw"></p></small></pre>
      <strike id="ya0vw"></strike>
    3. <code id="ya0vw"></code>

      www.247cinema.cn 提示:

      本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

      取消 確定

      3SBio Group has always been committed to solving the problem of
      clinical drug use for patients, constantly conquering the challenges
      of the disease, using high-quality drugs to improve the quality of
      life of patients, and working hard for the benefit of human health.

      Cooperation partners

      • Exclusive license for the commercialization of GLP-1 products in China

      • Exclusive license to develop and commercialize programmed therapeutic cells in Greater China

      • Exclusive license for the distribution and promotion of insulin products

      • Collaboration for clinical development and commercialization of MCM1 in China

      • Exclusive partnership to commercialize liposomal products utilizing NanoX? in Mainland China

      • Priority for potential licensing or development of two ophthalmic-related disease products

      • Exclusive right to develop and commercialize Remitch in China

      • Partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology

      • Collaboration for clinical development and commercialization of multiple biosimilars in China

      • Potential licensing priorities for four inner ear disease related research products

      • Investment to research and develop early stage cancer drugs